Press Releases

Date Title View
Toggle SummaryAugust 5, 2019 GenMark Diagnostics Reports Second Quarter 2019 Results
CARLSBAD, Calif. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2019 . Highlights Recognized total revenue of $18.4
View HTML
Toggle SummaryJuly 25, 2019 GenMark Diagnostics to Participate in the Canaccord Genuity Growth Conference
CARLSBAD, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA.
View HTML
Toggle SummaryJuly 22, 2019 GenMark Diagnostics Schedules Second Quarter 2019 Financial Results Conference Call for August 5, 2019
CARLSBAD, Calif. , July 22, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close on Monday, August 5, 2019. Management will hold a conference call to review the company's financial
View HTML
Toggle SummaryMay 23, 2019 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , May 23, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in three upcoming investor conferences.
View HTML
Toggle SummaryMay 1, 2019 GenMark Diagnostics to Present at the Bank of America Merrill Lynch Health Care Conference
CARLSBAD, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the Bank of America Merrill Lynch Heath Care Conference in Las
View HTML
Toggle SummaryApril 30, 2019 GenMark Diagnostics Reports First Quarter 2019 Results
CARLSBAD, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended March 31, 2019 . Highlights Recognized total revenue of $21.5
View HTML
Toggle SummaryApril 30, 2019 GenMark Diagnostics Expands Commercial Team
CARLSBAD, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has expanded its commercial team in North America with the addition of Michael Harkins as Senior
View HTML
Toggle SummaryApril 15, 2019 GenMark Diagnostics Schedules First Quarter 2019 Financial Results Conference Call for April 30, 2019
CARLSBAD, Calif. , April 15, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, April 30, 2019. Management will hold a conference call to review the company's financial
View HTML
Toggle SummaryApril 15, 2019 GenMark Diagnostics Receives FDA 510(k) Market Clearance for its ePlex Blood Culture Identification Gram-Negative Panel
Complete Suite of ePlex Blood Culture Identification Panels Now Available in the U.S. CARLSBAD, Calif. , April 15, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received
View HTML
Toggle SummaryFebruary 21, 2019 GenMark Diagnostics Reports Fourth Quarter and Full Year 2018 Results
CARLSBAD, Calif. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2018 .
View HTML